Scientific Online Resource System

Varna Medical Forum

Magnetic resonance diffusion and perfusion for differentiation of low grade from high grade glioma

Radoslav Georgiev, Boyan Balev, Ara Kaprelyan, Marianna Novakova

Abstract

Gliomas are the most common primary brain tumors with an annual incidence of 5-10 cases per 100,000 in Western populations. They are the leading cause of death among children and adults diagnosed with brain neoplasm. Gliomas are valued at the WHO classification by histopathological grades I to IV. Grades I and II are considered low-grade, while III, IV grades are high grade. Although they are histologically benign tumors most of II grade will transform into malignant grades III and IV in the range of 5-10 years of diagnosis. These grades are important because, they define therapeutic approach and prognosis in patients with gliomas. High grade gliomas were subjected to surgery and / or radiotherapy and / or chemotherapy, have a poor prognosis. Low-grade gliomas have sometimes conservative treatment. Conventional MR images provide important information on the presence of contrast enhancement, oedema, distant tumor foci, hemorrhage, necrosis, mass effect, etc., which are useful in the characterization of tumor aggressiveness and hence tumor grade. Modern techniques such as physiological techniques- MR diffusion and perfusion provide information about tumor physiology as microvascularity, angiogenesis, and cellularity, all of which are also important in determining the tumor grade. MR diffusion technique evaluates the structure of the tumor-cellularity, water content. MR perfusion technique is a marker for capillary density and neovascularisation.

Keywords

глиоми; степен на глиома; МР дифузия; МР перфузия

Full Text


References

Заболяемост от рак в България, 2011. Национален раков регистър. Том XXII, vol XXII, 2013, издателство Парадигма.

Aksoy FG, Lev MH. Dynamic contrastenhanced brain perfusion imaging: technique and clinical applications. Semin Ultrasound CT MR 2000;21:462-477.

Atlas SW, Lavi E (1996) Intraaxial brain tumors. In: Atlas SW (ed) Magnetic resonance imaging of the brain and spine, 2nd edn. Lippincott-Raven, Philadelphia, pp 423-488.

Behin A., Hoang-Xuan K., Carpentier A.F.,Delattre J.Y. Primary brain tumours in adults. The Lancet , 2003, 361: 323-331

Central Brain Tumor Registry of the United States (2006). http://www.cbtrus.org.

Cha S, Pierce S, Knopp EA, et al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 2001;22:1109-161.

De Angelis L.M. Brain tumors. N Engl J Med. 2001 Jan 11;344(2):114-23.

Gelderen P van et al.1994. Water diffusion and acute stroke. Magn Reson Med 31:154-163.

Hilario A. et al. The Added Value of Apparent Diffusion Coefficient to Cerebral Blood Volume in the Preoperative Grading of Diffuse Gliomas. AJNR Am J Neuroradiol 33:701- 07, Apr 2012

Holmes TM, Petrella JR, Provenzale JM. 2004. Distinction between cerebral abscesses and high-grade neoplasms by DSC perfusion MRI. AJR Am J Roentgenol 183: 1247-1252.

Huse JT, Phillips HS, Brennan CW. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011;59:1190-9.

Kang Yusuhn et al. Gliomas: Histogram Analysis of Apparent Diffusion Coefficient Maps with Standard- or High- b -Value Diffusion-weighted MR Imaging-Correlation with Tumor Grade. Radiology: Volume 261: Number 3-December 2011.

Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB. Stereotactic histologic correlations of computed tomography and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62:450-9.

Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010;177:2708-14.

Kitis O, Altay H, Calli C, et al. Minimum apparent diffusion coefficients in the evaluation of brain tumors. Eur J Radiol 2005; 55: 393-400.

Kleihues P., W. Cavenee. Pathology and genetics of tumors of the nervous system. IARC Press, Lyon (2000).

Law M, Oh S, Babb JS et Al: Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging prediction of patient clinical response. Radiology 238: 658-667, 2006.

Law M, Yang S, Wang H et Al: Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol24: 1989-1998, 2003.

Lee EJ, Lee SK, Agid R, Bae JM, Keller A, Terbrugge K. Properative grading of presumptive low-grade astrocytomas on MR imaging: diagnostic value of minimum apparent diffusion coefficient. AJNR 2008;29:1872-7.

Legler J.M., L.A. Ries, M.A. Smith et al. Cancer surveillance series: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst, 91 (1999), pp. 1382-1390.

Lev Michael H. et al. Glial Tumor Grading and Outcome Prediction Using Dynamic Spin-Echo MR Susceptibility Mapping Compared with Conventional Contrast-Enhanced MR: Confounding Effect of Elevated rCBV of Oligodendroglimoas. AJNR Am J Neuroradiol 25:214-221, February 2004.

Louis DN, Ohgaki H, Wiestler OD, Cavanee WK (eds). WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC; 2007.pp 1-306.

Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001 Jun 1;15(11):1311-33.

McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J. Treatment and survival of low-grade astrocytoma in adults-1977-1988. Neurosurgery. 1992 Oct;31(4):636-642.

Murakami R, Hirai T, Sugahara T, et al. Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. Radiology 2009;251(3):838-45.

Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P (2004). Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899.

Ohgaki H, Kleihues P (2005). Populationbased studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479-489.

Ohgaki H, Kleihues P (2007). Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453.

Romanowski CAJ, Hoggard N, Jellinek DA, Levy D, Wharton SB, Kotsarini C, Batty R, Wilkinson ID. Low grade gliomas. Can we predict tumour behaviour from imaging features? NRJ 2008; 21: 41-66.

Sadeghi N. et al. Apparent Diffusion Coefficient and Cerebral Blood Volume in Brain Gliomas: Relation to Tumor Cell Density and Tumor Microvessel Density Based on Stereotactic Biopsies. AJNR Am J Neuroradiol 29:476-82, Mar 2008.

Scherer HJ (1940). Cerebral astrocytomas and their derivatives. Am J Cancer 40:159-198.

Schiff, D., Brown, P. D. & Giannini, C. (2007). Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology, Vol. 69, No. 13, pp. (1366-73).

Scott JN, Brasher PM, Sevick RJ, et al. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002;59:947-9.

Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993 May 20;26(2):239-44.

Stark AM, Nabavi A, Mehdorn HM, Blömer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 2005;63(2):162-9.

Stejskal EO, Tanner JE(1965). Spin diffusion measurements: spin-echoes in the presence of a time-dependent field gradient. J Chem Phys 42:288-292.

von Deimling A, Burger PC, Nakazato Y, et al. Diffuse astrocytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC, 2007:25-9.

Walker C. et al. Biology, genetics and imaging of glial cell tumours. The British Journal of Radiology, 84 (2011), S90-S106.

Wessels P. H., Weber W. E. J., Raven G., Ramaekers F. C. S., Hopman A. H. N. et al. Supratentorial grade II astrocytoma : biological features and clinical course. Lancet Neurology , 2003, 2: 395-403.

Whittle IR. The dilemma of low-grade glioma. J Neurol Neurosurg Psychiatry 2004;75(Suppl II):ii31-ii36.

Wilson CB, Bramwell V, Bonfill X, et al. Central nervous system tumours. In: Williams C, ed. Evidence-based oncology. London: BMJ, 2003:561-4.




DOI: http://dx.doi.org/10.14748/vmf.v4i1.1148

Refbacks

Font Size


|